Project Grant R01HL172785

Award Date 6/1/24
Completion Date 2/28/29
Dollars Obligated $1.1M
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
This two-year, $200,000 project grant from the National Science Foundation's Computer and Information Science and Engineering program (CFDA 47.070) will support the development of interpretable deep learning methods and software for automated sleep phenotyping using multimodal health sensing data. Beth Israel Deaconess Medical Center will leverage polyssomnography data and novel radio frequency sensing techniques to build accurate deep learning models for classifying sleep stages and apnea...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,231,242 to develop and validate a diagnostic tool called Deep Learning-Enhanced Transmembranous Electromyography (DL-TMEMG) for detecting obstructive sleep apnea (OSA). The overarching objective is to create a convenient, accurate, and widely-usable point-of-care device for OSA diagnosis. In Phase 1, the project aims to establish the...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will provide $688,800.00 to the University of Chicago to investigate the role of obstructive sleep apnea (OSA) in glycemic dysregulation among adults with type 1 diabetes. The research study aims to determine how OSA impacts glycemic control in this population and examine the underlying...
This $684,116 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) aims to examine the mechanisms by which improving sleep regularity affects glycemic control and cardiovascular disease (CVD) risk in adults with type 1 diabetes. The grant will fund a 4-week behavioral sleep stability intervention in 80 adults with type 1 diabetes and irregular sleep...
This federal Project Grant award, provided by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), will fund research to determine the prevalence of undiagnosed obstructive sleep apnea (OSA) and its subtypes in primary care clinics, as well as develop efficient tools to identify OSA risk and subtypes. The total award amount is $740,271 with a project period from August 2024 to June 2029. The prime recipient, The Ohio State University,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, provides $678,710 to a collaborative research partnership between Henry Ford Health and Michigan State University Health Sciences. The project aims to validate a novel multi-sensor machine learning approach to precisely track sleep patterns in nightshift workers, a population critical to safety-sensitive operations who often suffer from impaired...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $711,226 to the University of California, Los Angeles (UCLA) to conduct research on the impacts of obstructive sleep apnea (OSA) on the brain. The objectives are to: 1) examine regional brain temperatures in OSA patients compared to controls; 2) assess whole-brain metabolite and antioxidant levels in OSA and controls; 3)...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,415,112 project grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Nebraska Medical Center (UNMC) to evaluate a telehealth-delivered adaptive intervention for improving continuous positive airway pressure (CPAP) therapy adherence and health outcomes in adults with obstructive sleep apnea (OSA). The project aims to: 1) compare effects of motivational enhancement, device support, and...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), will fund a 24-month clinical observational feasibility study to examine dental practitioners' oral appliance therapy (OAT) titration methods and outcomes for patients with obstructive sleep apnea (OSA). The $449,861 award will support the recruitment of 10 dental practitioners and 60 OSA patients within the South Texas Oral...
This Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports a randomized controlled trial to evaluate a couple-oriented behavioral therapy intervention to improve continuous positive airway pressure (CPAP) adherence among African American patients with obstructive sleep apnea (OSA) and their bed partners. The $1,474,280 award will fund a study involving 220 African American patients and their partners across 2 urban...

NEW MACHINE LEARNING METHODS FOR EXTRACTING FEATURES FROM DIGITAL HEALTH DATA WITH APPLICATIONS TO SLEEP APNEA - ABSTRACT WHILE OBSTRUCTIVE SLEEP APNEA (OSA) IS LINKED TO METABOLIC SYNDROME, THE RESULTS FROM RANDOMIZED CLINICAL TRIALS WITH POSITIVE AIRWAY PRESSURE (PAP) THERAPY, A TREATMENT FOR OSA, ARE INCONCLUSIVE REGARDING THERAPY EFFECTS ON GLUCOSE METABOLISM AND CARDIOVASCULAR DISEASE. CONTINUOUS GLUCOSE MONITORS (CGM) AND AMBULATORY BLOOD PRESSURE MONITORS (ABPM) ARE INCREASINGLY USED TO ELUCIDATE THE EFFECTS OF OSA ON GLUCOSE METABOLISM AND BLOOD PRESSURE, HOWEVER, THERE IS A LARGE GAP BETWEEN THE COMPLEXITY OF DATA FROM WEARABLE DEVICES AND COMMONLY USED CRUDE SUMMARY MEASURES (E.G., GLUCOSE TIME IN RANGE, 24H BLOOD PRESSURE MEAN). WITHOUT ADVANCEMENTS IN ALGORITHMS THAT PROVIDE BETTER CHARACTERIZATION OF TEMPORAL FEATURES IN CGM AND ABPM DATA, THE ADVERSE EFFECTS OF OSA ON GLUCOSE METABOLISM AND BLOOD PRESSURE WILL LIKELY REMAIN UNDERAPPRECIATED, AND ELUCIDATING THE HETEROGENEITY OF TREATMENT EFFECTS WITH PAP THERAPY WILL REMAIN DIFFICULT. OUR PROPOSAL IS MOTIVATED BY DATA FROM A RANDOMIZED CLINICAL TRIAL ON THE EFFECTS OF PAP THERAPY ON GLYCEMIC MEASURES AND BLOOD PRESSURE OF PATIENTS WITH CONCURRENT TYPE 2 DIABETES AND OSA. CONVENTIONAL CGM AND ABPM SUMMARIES LACK SENSITIVITY TO DIFFERENTIATE CONTROL AND TREATMENT GROUPS AND DETECT HETEROGENEITY IN TREATMENT EFFECTS. THE OVERALL OBJECTIVE OF THIS PROPOSAL IS TO DEVELOP NOVEL STATISTICAL AND MACHINE LEARNING METHODS TO FULLY EXPLOIT CGM AND ABPM DATA FOR PRECISION PHENOTYPING OF GLYCEMIC AND CARDIOVASCULAR MEASURES. TO ACHIEVE OUR OBJECTIVE, WE PROPOSE THE FOLLOWING: (1) TO ADDRESS THE LIMITED STATISTICAL POWER OF EXISTING METHODS FOR CHARACTERIZING FEATURES OF THE GLYCEMIC STATE, WE WILL DEVELOP A DISTRIBUTIONAL DATA ANALYSIS FRAMEWORK FOR CGM-BASED GLYCEMIC MEASURES THAT WILL INCORPORATE GLOBAL AND LOCAL TEMPORAL CHARACTERISTICS. (2) TO ADDRESS THE LIMITATIONS OF EXISTING METHODS FOR ABPM DATA DUE TO THE SEPARATE ANALYSIS OF EACH BLOOD PRESSURE MODALITY (SYSTOLIC, DIASTOLIC) AND OVERSIMPLIFIED DIVISION OF TIME INTO THE NIGHT (0-6 H) AND DAY, WE WILL DEVELOP A TENSOR DATA ANALYSIS FRAMEWORK FOR ABPM DATA THAT WILL INTEGRATE ALL CONCURRENT MEASUREMENTS (SYSTOLIC, DIASTOLIC, MEAN ARTERIAL PRESSURE, HEART RATE) ALIGNED BY THE FULL 24H TIME PERIOD. WE WILL DEVELOP SOFTWARE TO ENABLE THE BROAD APPLICATION OF PROPOSED ALGORITHMS TO OTHER STUDIES THAT COLLECT CGM AND ABPM DATA. COMPLETION OF THESE AIMS WILL PROVIDE THE NECESSARY ALGORITHMIC AND COMPUTATIONAL TOOLS TO TEST WHETHER BEHAVIORAL INTERVENTIONS AND NEW PHARMACOTHERAPEUTIC AGENTS IMPROVE THE GLYCEMIC STATUS AND BLOOD PRESSURE IN POPULATION SUBSETS, INCLUDING THOSE WITH PREDIABETES AND HYPERTENSION. REDUCING THE METABOLIC AND CARDIOVASCULAR RISK BURDEN HAS UNQUESTIONABLE RELEVANCE FOR THE PREVENTION OF CARDIOVASCULAR MORBIDITY AND MORTALITY.

Posted 5/22/24, 12:00 AM